Nebivolol

Nebivolol works by selectively blocking β1‑adrenergic receptors in the heart, which reduces sympathetic stimulation, slows heart rate, and decreases myocardial contractility, leading to lower blood pressure. At the same time, it activates endothelial nitric‑oxide synthase, increasing nitric‑oxide release that relaxes vascular smooth muscle and produces vasodilation. This dual action contributes to its antihypertensive and heart‑failure benefits.

Dosage of Nebivolol is individualized by the prescribing clinician based on the patient’s blood pressure, heart‑failure status, renal and hepatic function, and concomitant medications. The prescriber determines the appropriate starting dose and any subsequent titration, following local labeling and clinical guidelines. Patients should follow the exact regimen provided on the prescription label.

Safety of Nebivolol during pregnancy and lactation has not been definitively established. Animal studies have shown adverse developmental effects, and human data are limited. Consequently, the drug should be prescribed during pregnancy or while breastfeeding only when the potential therapeutic benefit justifies the possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation, including compliance with local regulations.

Compared with older non‑selective beta‑blockers such as propranolol, Nebivolol offers higher β1 selectivity and an additional nitric‑oxide mediated vasodilatory effect, which may result in fewer metabolic side effects and better tolerability. Relative to agents like atenolol, it often provides comparable blood‑pressure reduction with a lower incidence of fatigue and sexual dysfunction, though individual response varies.

Nebivolol should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or near heat sources. Do not use the medication after the expiry date printed on the label.

Nebivolol is administered orally, typically as a tablet that is swallowed whole with a glass of water. It may be taken with or without food, but patients should follow the specific instructions provided by their healthcare professional to ensure consistent absorption. The dose is usually taken once daily, and the tablet should not be chewed or crushed.

The most serious risks of Nebivolol include severe bradycardia, marked hypotension, and bronchospasm in patients with underlying airway disease. These events can lead to syncope, cardiac arrest, or respiratory failure and require immediate medical attention. Patients should be monitored closely for any signs of these critical reactions.

Nebivolol is contraindicated in individuals with second‑degree or higher atrioventricular block without a functioning pacemaker, severe sinus bradycardia, cardiogenic shock, and in patients with known hypersensitivity to the drug or any of its excipients. It should also be avoided in patients with uncontrolled asthma or severe chronic obstructive pulmonary disease.